Dr. Lal Pathlabs Limited — Investor Presentation 2021

Feb 5, 2021

==> picture [24 x 39] intentionally omitted <==

==> picture [251 x 29] intentionally omitted <==

February 5, 2021

National Stock Exchange of India Bombay Stock Exchange Limited Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Sandra Kurla Complex Sandra (E) Dalal Street Mumbai - 400 051. Mumbai- 400001

Subject: Corporate Presentation Q3 FY 21

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Regulations"), please find attached herewith Corporate Presentation of the Company for Q3 FY 21, which the Company proposes to share with analysts/investors.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

==> picture [76 x 51] intentionally omitted <==

Rajat Kalra Company Secretary and Legal Head Encl: As above

==> picture [74 x 73] intentionally omitted <==

==> picture [301 x 7] intentionally omitted <==

Regd. Office: Dr. Lal Pdltllabs Ud., 8luck E, Sector- I 8, Roh,ni, New Delhi - 110085, +91-11-30256600. Fax: +91-1 l -2788-2134 Corporate Office: Dr. Lal PdltlLabs ltct 12th Floor. Tower 8, SAS Tower, 1v'edicity, Sector-38, Gurugram - 122 001, Haryana -91-124-3016-500. Fax: T9l-124-4234-46€

==> picture [721 x 406] intentionally omitted <==

----- Start of picture text -----

Dr. Lal PathLabs Limited (DLPL)
Corporate
Presentation
February 2021
----- End of picture text -----

Disclaimer

By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person.

2

Table of Contents

==> picture [313 x 30] intentionally omitted <==

----- Start of picture text -----

Company overview
----- End of picture text -----

==> picture [313 x 30] intentionally omitted <==

----- Start of picture text -----

Investment highlights
----- End of picture text -----

==> picture [313 x 31] intentionally omitted <==

----- Start of picture text -----

Q3 FY21 highlights & financial performance
----- End of picture text -----

==> picture [313 x 31] intentionally omitted <==

----- Start of picture text -----

DLPL strategy for future growth
----- End of picture text -----

==> picture [45 x 130] intentionally omitted <==

----- Start of picture text -----

4
9
21
34
----- End of picture text -----

DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Company’s business operations remain subject to undetermined contingencies and risks. Dr. Lal PathLabs Limited would not be liable for any action undertaken based on such ‘forward-looking’ statements and does not commit to revising/updating thempublicly.

==> picture [80 x 26] intentionally omitted <==

3

==> picture [721 x 64] intentionally omitted <==

Company Overview

Dr. Lal PathLabs at a glance Our Evolution Dr. Lal PathLabs overview Experienced Management team

==> picture [278 x 226] intentionally omitted <==

==> picture [80 x 26] intentionally omitted <==

4

Dr. Lal PathLabs – At a Glance

70+ years of experience India’s Leading & Trusted Diagnostics Company	Largest diagnostics chain in the*			12% 3 Year Revenue CAGR				15% 3-Year PAT CAGR 120% Equity Dividend for FY 19-20
in the field of diagnostics 77.5 Mn patients serviced in last 5 years	country with PAN India presence and consistent track record of			~67% ROCE Excl. Cash & Investments				Rs 932.6 Cr. Cash & Investments as on 31st Dec 20
33 NABL accredited Labs; National Reference Lab accredited by CAP	quality and growth			216 Labs; Geographically spread out network				CRISIL AA- /Stable Long Term Rating; Strength of Balance 4,953 Pathology & Radiology tests; Comprehensive Test menu
								Sheet

As on March 31, 2020

*Largest on the basis of Revenue and presence

==> picture [80 x 26] intentionally omitted <==

5

Our Evolution

2010 – 2015 Strong position in North India, building network in other geographies

==> picture [324 x 127] intentionally omitted <==

----- Start of picture text -----

1949 – 2005
2005 – 2010
Foundation
Building
capabilities for
scale up 
Founded by Dr. Major S. K. 
----- End of picture text -----

2015 onwards

==> picture [80 x 46] intentionally omitted <==

Higher contribution from Rest of India, Commissioned state of the art Kolkata Reference Lab

• Investment by TA Associates

• 1949: Founded by Dr. Major S. K. Lal

• Clinical laboratories expansion in North region

• Higher contribution from Rest of India business & focus on bundled test program “Swasthfit”

• 1995: Company incorporated as Dr. Lal PathLabs Private Ltd.

• Growing the business in East region

• 2005: onwards: Investment by

• 2000: Three clinical labs receive WestBridge Capital NABL[1] accreditation

• Entry into the South and West regions

  • Successful commissioning of Regional Reference Lab at Kolkata in 2018

• 2008: Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited

• 2001: Received ISO 9001:2008 certification

• Multiple acquisitions to scale network

• Inorganic growth through acquisition of laboratories in Western & Southern India

• 2002: Received ’International  2010: National Reference Lab set Accreditation’ from CAP[2] up in Delhi

• Successful IPO listing in Dec 2015

• NABL: National Accreditation Board for Calibration and Testing Laboratories. 2. CAP: College of American Pathologists.

==> picture [80 x 26] intentionally omitted <==

6

Dr. Lal PathLabs overview

Established consumer healthcare brand in diagnostic services

Pan-India integrated coverage with 216 clinical labs (including National Reference Lab[1] at Delhi and Regional Ref Lab at Kolkata), 3 ,095 Patient Service Centers (PSCs) and 6,995 Pick-up Points (PUPs)[2]

Catalogue of 455 test panels, 2,537 pathology tests and 1,961 radiology and cardiology tests[2]

Collected and processed ~13.5 mn samples from ~5.5 mn patients in Q3 FY21; ~47.7 mn samples from ~19.4 mn patients in FY20; ~41.8 mn samples from ~17.6 mn patients in FY19

Customers include individual patients, corporates and institutions, healthcare providers as well as hospital and clinical labs (lab management)

FY20: Revenue: INR 1,330.4 Cr. ; EBITDA: INR 331.1 Cr[3] (Margin: 24.9% ); PAT: INR 227.6 Cr (Margin: 17.1% ); FY19: Revenue: INR 1,203.4 Cr ; EBITDA : INR 313.2 Cr (Margin: 26% ); PAT: INR 200.5 Cr (Margin: 16.7% )

1. Total area of 7,253 square meters

2. As on March 31, 2020.

3. Normalised EBITDA excl ESOP, CSR Cost & impact of Ind AS 116

==> picture [353 x 277] intentionally omitted <==

----- Start of picture text -----

Routine testing Specialized testing
Bio- Molecular
chemistry diagnostics
Hematology
Flowcytometry
Clinical pathology
Microbiology Genetics / Cytogenetics
Basic radiology Histopathology
ISO15189:2007
33 Labs
IS9001:2008
ISO27001:2013
Test Menu
Accreditations
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

==> picture [6 x 7] intentionally omitted <==

----- Start of picture text -----

7
----- End of picture text -----

Experienced Management team

==> picture [686 x 182] intentionally omitted <==

----- Start of picture text -----

(Hony.) Brig. Dr. ArvindLal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel
Executive Chairman Managing Director Whole-time Director Chief Executive Officer Chief Financial Officer
Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg
Company Secretary and Compliance
Chief Operating Officer Chief Information Officer Chief Human Resources Officer
Officer
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

8

==> picture [721 x 64] intentionally omitted <==

Investment Highlights

==> picture [278 x 226] intentionally omitted <==

==> picture [80 x 26] intentionally omitted <==

9

Investment Highlights

==> picture [649 x 340] intentionally omitted <==

----- Start of picture text -----

Well-positioned in one of the
Established consumer healthcare
fastest-growing segments of the
brand in diagnostic services
Indian healthcare industry
Attractive operating metrics and Scalable model integrated through
multiple levers in place to drive next centralized IT platform allows for
phase of growth network expansion
Robust financial
performance and return on
invested capital
10
----- End of picture text -----

Indian Healthcare Services is a large growth opportunity

==> picture [79 x 22] intentionally omitted <==

==> picture [155 x 25] intentionally omitted <==

==> picture [134 x 22] intentionally omitted <==

==> picture [63 x 21] intentionally omitted <==

India’s expected FY20 India healthcare Private expenditure on India GDP in FY20[1] population in 2022 expenditure healthcare in 2015

==> picture [624 x 179] intentionally omitted <==

----- Start of picture text -----

India, highly
underpenetrated
17.1% Total Healthcare Expenditure as % of GDP (2015)
market
11.2%
8.9%
8.2%
5.6% 5.3%
4.3% 3.9%
3.3%
US Germany Brazil South Africa Russian Federation China Singapore India Indonesia
----- End of picture text -----

Source: CRISIL Report titled “Assessment of Diagnostics Industry in India”.

1. Financial Year ending March 31st.

2. Source: Report of the Insurance Regulatory and Development Authority (“IRDA”)

3. Source: World Health Organization Global Health Expenditure database, October 2017, 4. IMF

==> picture [11 x 7] intentionally omitted <==

----- Start of picture text -----

11
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

INR 596 Bn Diagnostic Services industry expected to grow to INR 924 Bn in 2022

Diagnostic Services Industry Size

==> picture [143 x 130] intentionally omitted <==

----- Start of picture text -----

INR 924 Bn
INR 596.1 Bn
2017-18E 2021-22P
----- End of picture text -----

Screening, early detection, and monitoring reduce downstream costs

==> picture [312 x 289] intentionally omitted <==

----- Start of picture text -----

Growth Drivers
Increase in
Demand
evidence-based
for lifestyle
treatments
diseases-related
services
to grow
Focus on
preventive
diseases and
wellness
----- End of picture text -----

Source: Industry Reports, I-Sec Research

==> picture [11 x 7] intentionally omitted <==

----- Start of picture text -----

12
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

Diagnostic Services industry remains highly fragmented

==> picture [377 x 247] intentionally omitted <==

----- Start of picture text -----

Highly Fragmented Industry
Large
Standalone Pan-India
Centres, 48% Chains 35-40%
Diagnostic
Chain, 15%
Regional
Chains
60-65%
Hospital
Based, 37%
----- End of picture text -----

Largely fragmented and unorganized

Source: CRISIL Report titled “Assessment of Diagnostics Industry in India”.

==> picture [80 x 26] intentionally omitted <==

13

Established consumer healthcare brand in Diagnostic Services

Pillar of a Strong Brand

==> picture [695 x 283] intentionally omitted <==

----- Start of picture text -----

Pillar of a
Strong Brand
Medico Marketing
Doctor
Online
 Accreditations from CentreCall Query Handling Registration
CAP, NABL and ISO Offline
Accreditations
 Centrally administered
surveillance programs
Online Customer Lab
 Coverage in metros, Report Delivery Sample Collection
Tier 1 and Tier 2 cities Nationwide Offline Home
 Wide reach through Network
PSCs and PUPs
Retail Marketing Digital Marketing
 24x7 access including
online access and Fast Single brand pulls Walk-in customers Diverse and large
account for highest
home collection Turnaround patients customer pool
share of revenues
 Dedicated logistics Time
team
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

14

Scalable Model integrated through centralized IT platform allows for network expansion

==> picture [670 x 283] intentionally omitted <==

----- Start of picture text -----

Hub and Spoke Model Network Expansion
PSC PSC
No. of
Reference Clinical No. of PSCs No. of PUPs
Lab Laboratories
6,995
216 6,426
3,095
Clinical Clinical
5,624
Lab Lab 2,569
2,153
200
PSC PSC
PSC PSC
193
• Centralized diagnostic testing provides
greater economies of scale
• PSCs and PUPs facilitate penetration
FY18 FY19 FY20 FY18 FY19 FY20 FY18 FY19 FY20
within region and expand reach
----- End of picture text -----

1. Includes National Reference Laboratory and Regional Reference Lab in Kolkata

==> picture [80 x 26] intentionally omitted <==

15

Scalable Model integrated through centralized IT platform allows for network expansion

Integrated National Network…

…backed by Centralized IT platform which fully integrated network

Enterprise Resource Planning (ERP) System

• Payables, receivables, inventory, ledgers etc.

• Scalability and connectivity – web-based

Laboratory Information Management System

• Bi-directional interface; tracks specimen collection, shipping and testing in real time

• Assigns unique ID / barcode for each sample

Data Collection and Analytics

National Reference Laboratory Regional Reference Laboratory Clinical Laboratories Patient Service Centers

• Improve diagnostic services via data analyses

• Demand for tests are analyzed using past data

==> picture [80 x 26] intentionally omitted <==

16

Collection network

LPL’s scalable business model provides strategic advantage for expansion and consolidation

==> picture [689 x 191] intentionally omitted <==

----- Start of picture text -----

National Reference Lab & Regional
Ref. Lab
Single brand pulls patients
Clinical Labs
(Testing/Collection)
Walk-in customers account for
Patient Service Centers Pickup Points highest share of revenues
Home
Walk-ins
Collection Hospitals Doctors Labs Diverse, large customer pool
Walk-ins offers monetization
opportunities
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

17

Attractive operating metrics

==> picture [349 x 176] intentionally omitted <==

----- Start of picture text -----

No. of patients No. of samples
(Mn) (Mn)
CAGR: 13.0% CAGR: 17.2%
19.4 47.7
17.6 41.8
15.2
34.7
FY18 FY19 FY20 FY18 FY19 FY20
----- End of picture text -----

• Consumer brand and network expansion driving patient volumes

• Increase in samples with patient volumes growth

==> picture [217 x 263] intentionally omitted <==

----- Start of picture text -----

Total Revenue
(INR Cr.)
CAGR: 12.2%
1,330.4
1,203.4
1,056.9
FY18 FY19 FY20
 FY20 Revenues increased on
account of :

Marked gains in patient volumes
at 10.3%

Increase in tests per patient at
----- End of picture text -----

• Increase in tests per patient at 2.5 vs 2.4

==> picture [80 x 26] intentionally omitted <==

18

Robust financial performance

EBITDA[[*]] ,PAT and Return on Net Worth (INR Cr./%)

==> picture [658 x 297] intentionally omitted <==

----- Start of picture text -----

Total Revenue South Others EBITDA [[]] ,PAT and Return on Net Worth
India 3% (INR Cr./%)
(INR Cr.)
West 6%
CAGR: 12.2% India
8% 331.1
1,330.4 313.2
278.3
1,203.4
1,056.9 East 227.6
200.5
India Revenue by 171.8
14% Geography
(FY20)
Delhi &
NCR FY18 FY19 FY20
Rest of 40% EBITDA before ESOP Expense ,CSR & PAT
North India Ind AS 116 impact []
FY18 FY19 FY20 29%
EBITDA Margin
Before ESOP,
26.3% 26.0% 24.9%
CSR & Ind As 116
impact
• Growth driven primarily by increasing patient volumes and samples PAT Margin 16.3% 16.7% 17.1%
• Increase in operating margin due to economies of scale RONW 24.7% 23.0% 22.7%
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

19

Robust financial performance (Cont’d)

==> picture [411 x 232] intentionally omitted <==

----- Start of picture text -----

Fixed Asset Turnover [1] Cash and Cash Equivalents
Times (INR Cr.)
8.5x
7.5x
580.0
6.6x 522.9
405.8
184.8
144.8 164.3
FY18 FY19 FY20 FY18 FY19 FY20
----- End of picture text -----

• Self funded growth on account of strong cash flow generation

• Attractive fixed asset turnover ratio given assetlight model

• Current net cash position and internal accruals expected to fund next phase of growth

Cash and Bank Balance Current Investments

1. Fixed Asset Turnover = Total Revenue / Net PP&E as per Ind AS

==> picture [11 x 7] intentionally omitted <==

----- Start of picture text -----

20
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

==> picture [721 x 64] intentionally omitted <==

Q3 FY21 Highlights & Financial Performance

==> picture [278 x 226] intentionally omitted <==

==> picture [80 x 26] intentionally omitted <==

21

Q3 FY21 Snapshot

==> picture [592 x 233] intentionally omitted <==

----- Start of picture text -----

38.0% 62.7% 74.7%
INR 452.4 Cr INR 144.6 Cr INR 95.9 Cr
Revenues Normalised EBITDA PAT
15.3% 16.4%
~5.5 mn ~13.5 mn
Patients Samples
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

22

Overview of Dr. Lal PathLabs

==> picture [38 x 42] intentionally omitted <==

==> picture [41 x 31] intentionally omitted <==

==> picture [638 x 179] intentionally omitted <==

----- Start of picture text -----

Established brand Pan-India integrated Varied Offerings Unique and successful
coverage operating model
216 clinical labs (including
National Reference Lab at Catalogue of 455 test panels, Scalable model integrated
Established consumer
Delhi and Regional Reference 2,537 pathology tests and through centralised IT
healthcare brand in diagnostic
lab at Kolkata), 3,095 Patient 1,961 radiology and platform allows for network
services
Service Centers (PSCs) and cardiology tests expansion
6,995 Pick-up Points (PUPs)
----- End of picture text -----

Well-positioned in one of the fastest-growing segments of the Indian healthcare industry

==> picture [80 x 26] intentionally omitted <==

As on March 31, 2020

23

COVID, COVID Allied & Non-COVID Revenue

==> picture [295 x 240] intentionally omitted <==

----- Start of picture text -----

Rs. Cr.
355
347
209
74 81
56
11 16
1
Q1 FY21 Q2 FY21 Q3 FY21
Non COVID COVID COVID Allied
COVID includes RTPCR and Antibody tests
----- End of picture text -----

• Recorded an all time high Quarterly revenue of Rs 452.4 Cr in Q3 FY 21 backed by growth in Non-COVID business.

• Non-COVID growth at 8.3% in Q3 FY21

• Contribution from COVID & Allied business in Q3 FY21 is 21.6%

• 5.27 lac COVID RTPCR tests conducted in Q3 FY21 and 10.3 lac YTD Dec’20

• RT-PCR test being conducted in 11 labs.

• **COVID Allied includes IL-6 & D-Dimer

==> picture [80 x 26] intentionally omitted <==

24

Key Performance Highlights

==> picture [649 x 39] intentionally omitted <==

----- Start of picture text -----

During Q3 FY21:
----- End of picture text -----

• Revenues increased by 38% Y-o-Y to Rs. 452.4 crore

• Normalised EBITDA (after eliminating the impact of stock based compensation & CSR) at Rs. 144.6 crore

• Profit After Tax at Rs. 95.9 crore, representing a growth of 74.7% over the corresponding quarter of last year

• Interim dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board

==> picture [649 x 40] intentionally omitted <==

----- Start of picture text -----

Cash, FDs and Mutual Funds at Rs. 932.6 crore as on December 31, 2020, an increase of Rs. 188 crores in 9
months of FY21
----- End of picture text -----

==> picture [649 x 39] intentionally omitted <==

----- Start of picture text -----

Business back on growth track and achieves all time high quarterly revenue in Q3 FY21
----- End of picture text -----

• Non-COVID business grew by 8.3% Y-o-Y to Rs. 355 crores in Q3 FY21

• The bundled test portfolio ‘Swasthfit’ contributed 13% to revenue in this quarter

==> picture [80 x 26] intentionally omitted <==

25

Financials

Particulars (Rs. Cr.)	Q3 FY21	Q3 FY20	Gr %	YTD Dec'20	YTD Dec'19	Gr %
Revenue	452.4	327.9	38.0%	1,150.3	1,028.7	11.8%
Expenditure EBITDA Stock based comp. & CSR cost	313.6 138.8 5.8	245.6 82.3 6.6		836.0 314.3 18.8	742.4 286.3 15.1
			68.7%			9.8%
Normalised EBITDA	144.6	88.9	62.7%	333.1	301.4	10.5%
Normalised Margins Other Income	32.0% 13.5	27.1% 13.8		29.0% 37.8	29.3% 43.0
PBT	128.9	73.4	75.6%	283.6	265.1	7.0%
Margins	28.5%	22.4%		24.7%	25.8%
PAT	95.9	54.9	74.7%	211.4	195.0	8.4%
Margins	21.2%	16.7%		18.4%	19.0%
EPS (Basic)	11.44	6.56	74.4%	25.23	23.48	7.4%
EPS (Diluted)	11.41	6.55	74.2%	25.16	23.42	7.4%

Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be influenced by certain occurrences in that quarter

==> picture [80 x 26] intentionally omitted <==

26

Financial Highlights

==> picture [314 x 135] intentionally omitted <==

----- Start of picture text -----

+38.0%
452.4
327.9
Revenue
Q3 FY20 Q3 FY21
----- End of picture text -----

All figures in Rs. Crore

• Revenue increased in Q3 FY21 by 38.0% to Rs. 452.4 crore. This is on account of :

• Volumes which increased by 15.3% and

• Revenue from COVID testing

• Realisation per patient in Q3 FY21 at Rs. 824, higher as compared to Rs. 688 in Q3 FY20

==> picture [153 x 71] intentionally omitted <==

----- Start of picture text -----

Normalised EBITDA (after
eliminating the impactof
stock based compensation,
and CSR costs)
----- End of picture text -----

==> picture [131 x 122] intentionally omitted <==

----- Start of picture text -----

+62.7%
144.6
88.9
Q3 FY20 Q3 FY21
----- End of picture text -----

• Normalised operating EBITDA (after eliminating the impact of stock based compensation and CSR costs) at Rs. 144.6 crore in Q3 FY21, higher by 62.7% Y-o-Y

• Q3 FY21 Normalised EBITDA margin (after eliminating the impact of stock based compensation and CSR costs) came in at 32.0%

Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be 27 influenced by certain occurrences in that quarter

==> picture [80 x 26] intentionally omitted <==

Financial Highlights

==> picture [309 x 144] intentionally omitted <==

----- Start of picture text -----

+75.6%
128.9
73.4
PBT
Q3 FY20 Q3 FY21
----- End of picture text -----

All figures in Rs. Crore

• PBT for Q3 FY21 at Rs. 128.9 crore vs. Rs. 73.4 crore in the corresponding quarter of last year, representing a growth of 75.6%

• Q3 FY21 PBT margin at 28.5%, as against 22.4% in the same period of last year

==> picture [153 x 71] intentionally omitted <==

----- Start of picture text -----

PAT
----- End of picture text -----

==> picture [131 x 129] intentionally omitted <==

----- Start of picture text -----

+74.7%
95.9
54.9
Q3 FY20 Q3 FY21
----- End of picture text -----

• PAT at Rs. 95.9 crore in Q3 FY21 as compared to Rs. 54.9 crore in Q3 FY20, higher by 74.7%

• Q3 FY21 PAT margin at 21.2% Vs. 16.7% in Q3 FY20

Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be influenced by certain occurrences in that quarter

28

==> picture [80 x 26] intentionally omitted <==

Management Commentary

Commenting on the results announcement, (Hony) Brig. Dr. Arvind Lal, Executive Chairman

“We have seen our business make further progress in returning to normalcy, and our non-COVID business has seen a sharp recovery. While COVID tests continue to be a significant contributor to our performance, we are making further inroads to grow our non-COVID business through menu expansion, deeper penetration in existing markets and selective inorganic acquisitions in newer markets. I believe this is working well for us and we remain confident to realize our growth objectives.”

Commenting on the results announcement, Dr. Om Manchanda, Managing Director

“The country is gradually returning to normalcy in many ways. India’s healthcare services sector too is on the same trajectory. Our effort to revive the non-COVID aspect of the operation was instrumental in conserving strategic momentum and has given us a base to chart further improvement. As industry leaders, we try to stay ahead of the curve when it comes to technology and innovation, which is geared towards improving the quality of services for our patients and providing them with a seamless experience.”

Commenting on the results announcement, Bharath Uppiliappan, Chief Executive Officer

“In Q3 FY21, we demonstrated encouraging performance smartly navigating through the aftermath of COVID-19 pandemic and related disruptions. The growth in this quarter is a testimony to the fact that we have fully recovered and are back on a robust growth trajectory in our Non-COVID business. Performance was driven by various initiatives undertaken by us over the past few quarters to maintain business continuity supported by demand reverting back to utmost normalcy.”

==> picture [80 x 26] intentionally omitted <==

29

Vibrant Outlook

Strongly develop Rest of India geographies, through Regional Reference Labs and cluster city approach for attractive markets

==> picture [648 x 247] intentionally omitted <==

----- Start of picture text -----

Target
to grow
Evaluate best fit inorganic Deeper Penetration within the
ahead
opportunities in South & West North, East & Central Indian
of the
markets
industry
Higher contribution from bundling of
tests – ‘Swasthfit’
----- End of picture text -----

==> picture [11 x 7] intentionally omitted <==

----- Start of picture text -----

30
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

Leveraging digital to make life easier for patient

==> picture [45 x 44] intentionally omitted <==

==> picture [48 x 48] intentionally omitted <==

==> picture [45 x 45] intentionally omitted <==

==> picture [44 x 35] intentionally omitted <==

==> picture [60 x 46] intentionally omitted <==

==> picture [41 x 40] intentionally omitted <==

• Logistics Lab Operations Business

• Digital Lab e-Commerce Mobile app Automation Automation Continuity Plan

• • Self Registration • Online test / health • Test booking, view • Field Executive • Totally integrated • ‘Multi Site’ model Kiosk for patients package booking and download Mobile App for Track with • Quick recovery in

• • Integrated payment • Online payment, current and Route Traceability & centralized LIMS for case of disaster gateway for online order related historical test Field Executive higher Output and • Real time Data payment notifications at reports Tracking faster processing, Replication

• • Self Report printing various touch points • Trend chart along • Real Time visibility built in analytics and between sites Kiosks for 24 by 7 • Integrated Cross with Cumulative of patient samples Business Intelligence • Centrally Report printing Channel Reporting capabilities Hosted and similar to a bank communication with • Find a Lab near you real time ATM strong automated • Self Monitoring – monitored backend using cloud, My Wellness predictive analytics & AI

• Phlebo Mobile App for home collection booking along with route plan.

==> picture [80 x 26] intentionally omitted <==

31

Shareholding as of 31st December, 2020

==> picture [629 x 272] intentionally omitted <==

----- Start of picture text -----

24.4%
FIIs
12.5%
55.2%
Others
Promoter and
Promoter
Group
7.9%
Mutual Funds
----- End of picture text -----*

*Mutual Funds includes Alternate Investment Funds as well

==> picture [80 x 26] intentionally omitted <==

32

Vision, Mission & Values

VISION

==> picture [684 x 203] intentionally omitted <==

----- Start of picture text -----

Customer First
Be the most trusted healthcare partner, enabling
healthier lives Ethics & Integrity
VALUES Quality
To be the undisputed market leader by providing
Accountability
accessible, affordable, timely and quality healthcare,
diagnostics, applying insights and cutting edge
technology to create value for all stakeholders Empathy & Compassion
----- End of picture text -----

==> picture [67 x 13] intentionally omitted <==

----- Start of picture text -----

MISSION
----- End of picture text -----

==> picture [80 x 26] intentionally omitted <==

33

==> picture [721 x 64] intentionally omitted <==

==> picture [278 x 226] intentionally omitted <==

DLPL Strategy for future growth

==> picture [80 x 26] intentionally omitted <==

34

DLPL Strategy for future growth

==> picture [649 x 332] intentionally omitted <==

----- Start of picture text -----

Strengthen
Expansion in
Existing
1 Offering 2
Operations
Expand
management of
Geographic
hospital based
4 expansion 3
and clinical
laboratories
35
----- End of picture text -----

DLPL Strategy for future growth

==> picture [689 x 46] intentionally omitted <==

Expand management of hospital Strengthen Existing Operations Expansion in Offering Geographic expansion based and clinical laboratories Boosting quality & reliability Improve breadth of Tap incremental contracts for Focus city & cluster approach standards diagnostic testing in sourcing test of hospitals and other clinical laboratories Improving turnaround times Set up more clinical Cutting edge technology for testing laboratories Preventive healthcare Tap polyclinics Set up Regional Reference Grow basic radiology practice screening Laboratories Online initiatives and data Chronic & Lifestyle disease Consider alliances and analytics mgmt. services acquisitions Expand reach in corporate Investment in branding segment

Focus city & cluster approach Set up more clinical laboratories Set up Regional Reference Laboratories Consider alliances and acquisitions

==> picture [80 x 26] intentionally omitted <==

36

Consistent investments in R&D

DSIR recognized In House R&D unit R&D Collaboration with marquee with an experienced team of institutions research scientists and doctors Jawaharlal Nehru University for development of diagnostics kit for detection of mycobacterium tuberculosis and mycoabacterial species CSIR-Institute of Genomics and Integrative Biology for acquisition of know-how for 27 diagnostic assays

Successful commercialization of tests

==> picture [68 x 55] intentionally omitted <==

• Spino-Bulbar-Muscular Atrophy

• Sickle Cell Trio Prenatal Mutation Detection

• Sanger Sequencing, Single Variant

• Leigh Syndrome Mitochondrial Mutation Detection

• Episodic Ataxia Type 2

==> picture [80 x 26] intentionally omitted <==

==> picture [11 x 7] intentionally omitted <==

----- Start of picture text -----

37
----- End of picture text -----

Genevolve: The Genomics initiative

==> picture [170 x 53] intentionally omitted <==

GENEVOLVE brings the dawn of a new era of Genomic testing!

Genevolve: Genomics division focuses on Genetic testing

Offers wide range of key tests related to Oncogenomics, Neurogenomics, Rare disease & Pre-natal/ Post-natal

Tests are carried out using cutting edge technologies such as Next Generation Sequencing (NGS), MLPA, ddPCR, FISH & Sanger Sequencing among others

==> picture [55 x 55] intentionally omitted <==

==> picture [54 x 9] intentionally omitted <==

----- Start of picture text -----

New Tests
----- End of picture text -----

• Sperm DNA

• Y Chromosome

==> picture [55 x 40] intentionally omitted <==

==> picture [63 x 12] intentionally omitted <==

----- Start of picture text -----

New Tie-ups
----- End of picture text -----

• Caris MI (USA)

• Caris Tumor Seek

==> picture [34 x 39] intentionally omitted <==

ONCOPATH

• Niche Segmentation

PAN India network of clinical laboratories, collection centers and pick- up points makes Dr. Lal PathLabs the most reliable genetic testing service provider in India

==> picture [80 x 26] intentionally omitted <==

38

In-house adoption of Digital Histopathology

• Reporting of Digital Breast cancer Panels using AI based algorithms

• Digital Histopathology for remote routine reporting

==> picture [288 x 285] intentionally omitted <==

Opportunities created by Digital Histopathology

•Enhanced access to second opinion, synchronous review of slides

• •Enhanced quality of reporting

• •Potential for insourcing services

• •Leveraging Artificial Intelligence for Histopathology

• •Potential for de-centralization of histopathology reporting

==> picture [80 x 26] intentionally omitted <==

39

Highest Quality Standards in the Industry

==> picture [678 x 302] intentionally omitted <==

----- Start of picture text -----

100+ Quality Digitally enabled
Real time quality Risk based improvement solutions
control quality assurance meetings on a daily implemented for
monitoring framework basis with the quality audits
network partners and trainings
Best in the Industry CAP Proficiency Testing Score at 98.3% for National Reference Lab
Consistently high EQAS Performance Testing Score at 98.7% for Satellite Labs
NABL Accreditation granted to 7 additional Labs for processing Covid-19 samples
40
----- End of picture text -----

Best in class Logistics and Supply Chain management

==> picture [721 x 335] intentionally omitted <==

----- Start of picture text -----

Real
Real time
time
service
sample
monitoring
tracking Control
tower
Real time
Automated
Field
Cash Productivity
Executive
and route
collection
tracking
planning
process
with clients visibility
24
----- End of picture text -----

Enhanced Customer Experience in Home Collection

==> picture [649 x 337] intentionally omitted <==

----- Start of picture text -----

Auto Routing engine to
dynamically allocate the
booking to nearest available
phlebotomist
Real time slot confirmation Real time phlebo visibility to
to patient the patient
Variable model which grows ECG at home service
with business volume launched in select cities
Automated and scalable
system
25
----- End of picture text -----

Key Awards & Recognition

==> picture [76 x 43] intentionally omitted <==

Dr. Om Manchanda honoured ICICI Lombard & CNBC EY Entrepreneur of The and awarded as ‘Healthcare TV18 India Risk Year 2019 – Life Personality of the Year, 2020’ Management Awards 2020 Sciences & Healthcare by FICCI – Emerging Corporates

Frost and Sullivan 4th Annual India Healthcare Excellence Award, 'Diagnostic Service Provider Company of the Year 2012'

Franchise India Excellence Award in Hall of Fame Category (2011, 2012)

Computerworld Honors Laureate Program, 2012

Data Quest Technology Award 2015 – Excellence in Implementation of Technology

Franchisor of the Year (Healthcare) - Franchise Plus Awards 2010

VC Circle Healthcare Summit 2013 – Best Diagnostic Company

Padma Shri – (Hony) Brig. Dr. Arvind Lal (2009)

==> picture [80 x 26] intentionally omitted <==

43

Contact Us

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 455 test panels, 2,537 pathology tests and 1,961 radiology and cardiology tests as on March 31, 2020.

As on March 31, 2020, DLPL’s has 216 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pick-up Points (PUPs). In FY19 & FY20, DLPL collected and processed approximately 41.8 million samples and 47.7 million samples from approximately 17.6 million and 19.4 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited: Corporate Identification No: L74899DL1995PLC065388 Website: https://www.lalpathlabs.com

Ved Goel / Rajat Kalra Siddharth Rangnekar / Nishid Solanki For further Dr. Lal PathLabs Limited CDR India information Tel: +91 124 301 6500 Tel: +91 22 66451209 / 1221 please contact: Fax: +91 124 423 4468 Fax: +91 22 66451213 E-mail: ved.goel@lalpathlabs.com/rajat.kalra@lalpathlabs.com Email: siddharth@cdr-india.com / nishid@cdr-india.com

==> picture [80 x 26] intentionally omitted <==

44